Carina Wehner

Title: The Innovative Contributions of Carina Wehner in Cancer Research

Introduction

Carina Wehner, based in Munich, Germany, is a notable inventor with a focus on cancer immunotherapy. With seven patents to her name, Wehner has made significant advancements in the field of T cell receptors that have the potential to transform cancer treatment.

Latest Patents

Wehner's most recent patents include innovations such as MAGEA1 specific T cell receptors and NYESO TCRs. The former relates to an isolated T cell receptor specific for a MAGEA1-derived peptide, which stands as a crucial component for developing a medicament aimed at cancer therapy. Similarly, the NYESO TCR patent involves an isolated T cell receptor specific for the NY-ESO-1/LAGE-1, also designed for the treatment of cancer. Both patents outline the creation of a multivalent TCR complex, as well as nucleic acids encoding these TCRs, and underscore their therapeutic implications in cancer treatment.

Career Highlights

Throughout her career, Carina Wehner has worked with innovative companies such as Medigene Immunotherapies GmbH and Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt. Her contributions in these organizations have further solidified her reputation as a leading inventor in the biotechnology sector.

Collaborations

Wehner has collaborated with esteemed colleagues including Christian Ellinger and Dolores Schendel. These partnerships have been critical in advancing research initiatives and enhancing the effectiveness of the innovations she has developed.

Conclusion

Carina Wehner's contributions to cancer research through her patents and collaborations reflect her commitment to pushing the boundaries of medical science. Her work in developing T cell receptors not only showcases her inventive prowess but also points towards a promising future in cancer therapeutics.